Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | PPIA | P62937 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | NEK2 | P51955 | 1/20 | 0.43 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6024058 | 0.89 | AURKA (0.50) | PPIAKDRCDK1CDK2 | |
| SCHEMBL5046278 | 0.85 | CDK19 (0.53) | SYKPPIASIRT2SIRT1SIRT3 | |
| SCHEMBL5039422 | 0.77 | PPIA (0.53) | SYKPPIA | |
| SCHEMBL13925826 | 0.77 | PPIA (0.41) | EGFRERBB2SYKPPIASIRT2 | |
| SCHEMBL13763843 | 0.77 | GSK3A (0.47) | EGFRERBB2SYKPPIA | |
| SCHEMBL15584703 | 0.73 | AURKA (0.53) | SYKPPIASIRT2CDK1CDK2 | |
| SCHEMBL5039414 | 0.73 | AURKA (0.53) | PPIASIRT2KDRCDK1CDK2 | |
| SCHEMBL6033968 | 0.72 | KDR (0.71) | SYKKDRCDK1 | |
| SCHEMBL5546967 | 0.71 | XDH (0.52) | CDK2 | |
| SCHEMBL6033889 | 0.70 | KDR (0.68) | EGFRERBB2SYKKDRCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1442024-B1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-03-19 | — | — | EP | claimed |
| US-20060063789-A1 | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | US | claimed |
| EP-1442024-A1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-04 | — | — | EP | claimed |
| WO-2003037877-A1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | claimed |
| EP-1442024-B1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-03-19 | — | — | EP | disclosed |
| US-20060063789-A1 | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | US | disclosed |
| EP-1442024-A1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037877-A1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063789-A1 | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | GSK3B, GSK3A, PHKG1 | EGFR 1235/4885ERBB2 523/4885SYK 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.